Cancer Family
Childhood Nervous System Neoplasm
CI-CAN-00000136Explore in graph →
- NCIt
- C188950
Loading cancer entity…
Cancer Family
CI-CAN-00000136Explore in graph →
Variants & evidence
41 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ATRX Underexpression1 | ||||||||
| (prognostic) | Childhood Low Grade Glioma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID7190Loss of ATRX was identified in 12 of 247 patients with PLGGs using immunohistochemistry. Survival analysis showed that ATRX loss was associated with adverse overall survival (p<0.0001) and progression… (full text at CIViC) PMID 29948154 · Yang et al., 2018 · Open in CIViC | civic |
| BRAF Kinase Domain Duplication1 | ||||||||
| (oncogenic) | Childhood Visual Pathway GliomaALIAS | Oncogenic | B | Supports Oncogenicity | 4 | submitted | EID12471Fluorescence in situ hybridization (FISH) studies were performed using home brew probes targeting 3′ BRAF, 5′ BRAF, and a commercial CEP7 probe on 59 patients with optic nerve glioma. Duplication of t… (full text at CIViC) PMID 22892521 · Rodriguez et al., 2012 · Open in CIViC | civic |
| BRAF V6001 | ||||||||
| Dabrafenib | Childhood Low Grade Glioma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID8034This clinical trial used a cohort of 32 pediatric low grade glioma (pLGG) patients. The primary endpoint of this study was objective response rate (ORR). In this study, an ORR of 44% and a 1-year prog… (full text at CIViC) PMID 31811016 · Hargrave et al., 2019 · Open in CIViC | civic |
| BRAF V600E3 | ||||||||
| (prognostic) | Childhood Low Grade Glioma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID7191Using Sanger sequencing, BRAFV600E mutations were identified in 21 of 285 patients with PLGGs (7.4%). This mutation was enriched in hemispheric tumors (p<0.007) and was associated with shorter progres… (full text at CIViC) PMID 29948154 · Yang et al., 2018 · Open in CIViC | civic |
| Selumetinib | Childhood Pilocytic Astrocytoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7485In a phase 2 trial, patients with pediatric low-grade glioma after at least one standard therapy were treated with MEK1/2 inhibitor selumetinib. In stratum 1, nine patients with WHO grade I pilocytic… (full text at CIViC) PMID 31151904 · Fangusaro et al., 2019 · Open in CIViC | civic |
| Vemurafenib | Childhood Pilocytic Astrocytoma | Predictive | C | Supports Sensitivity Response | ||||
| BRAF V600E + BRAF Fusion1 | ||||||||
| Tovorafenib | Childhood Low Grade Glioma | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID12016In this ongoing phase 2 trial (FIREFLY-1), 76 patients, aged 6 months to 25 years, with pediatric low-grade glioma harbouring BRAF alterations (BRAF fusions or BRAF V600E mutations) were treated with … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC | civic |
| BRAF V600 + BRAF Fusion1 | ||||||||
| Tovorafenib | Childhood Low Grade Glioma | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID12028In this phase 2 clinical trial, the efficacy of RAF inhibitor tovorafenib (DAY-101) was investigated in patients between the ages of 6 months and 25 years, with pediatric low-grade gliomas harbouring … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC | civic |
| LEUTX Fusion1 | ||||||||
| (diagnostic) | Childhood Central Nervous System Embryonal CarcinomaALIAS | Diagnostic | B | Supports Positive | 2 | submitted | EID12698Across a multicenter cohort of CNS embryonal tumors (n = 9), recurrent BRD4::LEUTX fusions were identified by RNA sequencing, with all cases retaining LEUTX exon 2 and variable BRD4 breakpoints (exons… (full text at CIViC) PMID 38500181 · Andreiuolo et al., 2024 · Open in CIViC | civic |
| BRD4 Overexpression1 | ||||||||
| JQ1 | Childhood Medulloblastoma | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID9316Predominantly high-level expression of BRD4 was found in the majority of medulloblastoma cell lines examined (HD-MB3, ONS-76, UW-228, D-341, and D-283); the exception being the Daoy cell line exhibiti… (full text at CIViC) PMID 24231268 · Henssen et al., 2013 · Open in CIViC | civic |
| CDKN2A Deletion1 | ||||||||
| (prognostic) | Childhood Low Grade Glioma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID7192CDKN2A deletion was identified in 24 of 273 patients with PLGGs using FISH analysis. An association between this alteration and BRAFV600E was detected (p=0.0001). Hemispheric tumors with CDKN2A deleti… (full text at CIViC) PMID 29948154 · Yang et al., 2018 · Open in CIViC | civic |
| LEUTX Fusion1 | ||||||||
| (diagnostic) | Childhood Central Nervous System Embryonal CarcinomaALIAS | Diagnostic | C | Supports Positive | 2 | submitted | EID10310This is a report about CIC-LEUTX gene fusion (CIC exon 20 to LEUTX exon 3 ) in a CNS embryonal tumor from a 2-year-old male, and the report also reviewed the clinical and pathological features of 3 ot… (full text at CIViC) PMID 33344249 · Hu et al., 2020 · Open in CIViC | civic |
| CTNNB1 Exon 3 Mutation3 | ||||||||
| (diagnostic) | Childhood Medulloblastoma | Diagnostic | B | Supports Positive | 4 | accepted | EID7967A total of 51 medulloblastomas from two independent cohorts (19 and 32 cases) were assessed for evidence of Wnt/Wg pathway activation, alongside a genome-wide analysis of associated copy-number aberra… (full text at CIViC) PMID 17172831 · Clifford et al., 2006 · Open in CIViC | civic |
| (prognostic) | Childhood Medulloblastoma | Prognostic | B | Supports Better Outcome | 4 | submitted | EID9013This retrospective study evaluated 72 pediatric medulloblastoma patients for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-cat… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC | civic |
| (diagnostic) | Childhood Medulloblastoma | Diagnostic | B | Supports Positive | 3 | |||
| CTNNB1 G34R1 | ||||||||
| (prognostic) | Childhood Medulloblastoma | Prognostic | C | Supports Better Outcome | 3 | submitted | EID9014A retrospective study evaluated 72 pediatric medulloblastoma patients for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-cateni… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC | civic |
| CTNNB1 I35K1 | ||||||||
| (prognostic) | Childhood Medulloblastoma | Prognostic | C | Supports Better Outcome | 3 | submitted | EID9016A retrospective study evaluated 72 pediatric medulloblastoma patients for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-cateni… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC | civic |
| CTNNB1 S33F1 | ||||||||
| (prognostic) | Childhood Medulloblastoma | Prognostic | C | Supports Better Outcome | 4 | submitted | EID9015A retrospective study evaluated 72 pediatric medulloblastoma patients for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-cateni… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC | civic |
| ROS1 Fusion1 | ||||||||
| Entrectinib | Desmoplastic Infantile AstrocytomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11850In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (3 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| ERBB2 Amplification1 | ||||||||
| Lapatinib | Childhood Ependymoma | Predictive | B | Supports Sensitivity Response | 1 | accepted | EID9778From a phase one clinical trial, pediatric patients with refractory CNS malignancies were administered 300-1150 mg/m2 twice daily of ERBB2 and EGFR inhibitor lapatinib. The maximum-tolerated dose was … (full text at CIViC) PMID 20713864 · Fouladi et al., 2010 · Open in CIViC | civic |
| BRAF Fusion1 | ||||||||
| Everolimus + TrametinibCombination | Childhood Low Grade Glioma | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID7198This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with… (full text at CIViC) PMID 29156677 · Jain et al., 2017 · Open in CIViC | civic |
| FGFR1 Internal Duplication1 | ||||||||
| (diagnostic) | Childhood Low Grade Glioma | Diagnostic | B | Supports Positive | 4 | accepted | EID7203This GWAS study identified a structural variant of FGFR1. Duplication of the tyrosine kinase domain (TKD) of FGFR1 was found in 11 of 149 patients (13/151 tumor samples, including 2 recurrent tumors, … (full text at CIViC) PMID 23583981 · Zhang et al., 2013 · Open in CIViC | civic |
| H3-3A K28M2 | ||||||||
| (diagnostic) | Childhood Spinal Cord NeoplasmALIAS | Diagnostic | B | Supports Positive | 3 | submitted | EID9794Gessi, et al. (2015) studied 30 primary spinal diffuse high-grade gliomas (HGG) and 6 diffuse astrocytomas. The H3F3A p.K27M variant has been reported in 16 HGG (including 2 anaplastic gangliogliomas,… (full text at CIViC) PMID 26231952 · Gessi et al., 2015 · Open in CIViC | civic |
| 〃 | Childhood Spinal Cord NeoplasmALIAS | Diagnostic | C | Supports Positive | 3 | submitted | EID1080316 of 30 high-grade gliomas (HGG) were found to harbor K27M mutations. The frequency of mutations was similar between adults and children (52% vs 54%). PMID 26231952 · Gessi et al., 2015 · Open in CIViC | civic |
| H3-3A MUTATION1 | ||||||||
| (prognostic) | Childhood Low Grade Glioma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID7189Using Sanger sequencing, H3F3A mutations in patients with pediatric low-grade gliomas (PLGGs) were identified (K27M: 13/280; G34R: 5/280). Kaplan-Meier survival analysis showed that H3F3A mutations we… (full text at CIViC) PMID 29948154 · Yang et al., 2018 · Open in CIViC | civic |
| BRAF Fusion9 | ||||||||
| (prognostic) | Childhood Low Grade Glioma | Prognostic | B | Supports Better Outcome | 4 | accepted | EID7193KIAA1549-BRAF fusion was identified in 87 of 272 patients with PLGGs using Fluorescence In situ hybridization (FISH) analysis. This mutation was strongly associated with a greater progression-free sur… (full text at CIViC) PMID 29948154 · Yang et al., 2018 · Open in CIViC | civic |
| 〃 | Childhood Low Grade Glioma | Prognostic | B | Supports Better Outcome | 4 | accepted | EID7200Hawkins et al. (2011) retrospectively studied 70 consecutive patient with incompletely resected pediatric low-grade astrocytomas (PLGA). KIAA1549-BRAF fusion was identified in 60% of cases in this coh… (full text at CIViC) PMID 21610142 · Hawkins et al., 2011 · Open in CIViC | civic |
| PLX4720 + VemurafenibSubstitutes | Childhood Low Grade Glioma | Predictive | D | |||||
| MYB AMPLIFICATION1 | ||||||||
| (prognostic) | Childhood Low Grade Glioma | Prognostic | B | Supports Better Outcome | 4 | accepted | EID7194MYB amplification was detected in 28 of 263 patients with PLGGs using Fluorescence In situ hybridization (FISH) analysis. The amplification of MYB was strongly associated with greater progression-free… (full text at CIViC) PMID 29948154 · Yang et al., 2018 · Open in CIViC | civic |
| NF1 Mutation1 | ||||||||
| Selumetinib | Childhood Low Grade Glioma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID7487In a phase 2 trial, patients with pediatric low-grade glioma after at least one standard therapy were treated with MEK1/2 inhibitor selumetinib. In stratum 1, nine patients with WHO grade I pilocytic … (full text at CIViC) PMID 31151904 · Fangusaro et al., 2019 · Open in CIViC | civic |
| EGFR Fusion1 | ||||||||
| Gefitinib | Childhood Ependymoma | Predictive | A | Supports Sensitivity Response | 1 | submitted | EID10933SEC61G::EGFR (5'UTR::e14) (5'-UTR of SEC61G and 3'-UTR of EGFR) was detected in ependymoma as a change sensitive to gefitinib (also confirmed by mice xenografts model). Screening of 16 ependymoma pati… (full text at CIViC) PMID 29092923 · Servidei et al., 2017 · Open in CIViC | civic |
| TERT Promoter Mutation1 | ||||||||
| (prognostic) | Childhood Low Grade Glioma | Prognostic | C | Supports Poor Outcome | 4 | accepted | EID7188The aim of this Chinese study was to identify prognostic biomarkers for pediatric low-grade gliomas (PLGG). Approximately 300 patients were included. Using Sanger sequencing, mutations at TERT promote… (full text at CIViC) PMID 29948154 · Yang et al., 2018 · Open in CIViC | civic |
| MAMLD1 Fusion1 | ||||||||
| (diagnostic) | Supratentorial Ependymoma YAP1 Fusion-Positive | Diagnostic | B | Supports Positive | 4 | accepted | EID11888A total of 15 pediatric patients with supratentorial ependymomas harboring YAP1::MAMLD1 fusions were reported. In all 15 cases, YAP1::MAMLD1 fusions were confirmed by RT-PCR and sequencing. In the ma… (full text at CIViC) PMID 30246434 · Andreiuolo et al., 2019 · Open in CIViC | civic |
| SIRAL1 Fusion1 | ||||||||
| (diagnostic) | Supratentorial Ependymoma YAP1 Fusion-Positive | Diagnostic | C | Supports Positive | 1 | accepted | EID11889This is a case report of a 26-year-old male patient who sufferred 3 grand mal seizures and was found to have a left frontal lobe ependymoma with a YAP1::FAM118B fusion. No other genetic alterations we… (full text at CIViC) PMID 33480048 · Wang et al., 2021 · Open in CIViC | civic |
| YAP1 Fusion1 | ||||||||
| (diagnostic) | Supratentorial Ependymoma YAP1 Fusion-Positive | Diagnostic | B | Supports Positive | 4 | accepted | EID11890DNA methylation profiling of 500 ependymal tumors identified 9 molecular profiles with 3 occurring in the supratentorial compartment (designated ST EPN). RNA sequencing performed in 7 of the 13 cases… (full text at CIViC) PMID 25965575 · Pajtler et al., 2015 · Open in CIViC | civic |
Data updated 17 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| 3 |
| accepted |
EID3777In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years l… (full text at CIViC) PMID 25524464 · del Bufalo et al., 2014 · Open in CIViC |
| civic |
EID7965A series of 72 pediatric medulloblastomas were evaluated for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-catenin protein exp… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC |
| civic |
| 4 |
| submitted |
EID7204Activated BRAF protein kinase mutations are characteristic of pediatric astrocytomas with KIAA1549-BRAF fusion commonly observed in low-grade astrocytomas. Sievert et al. (2013) generated BRAF fusion … (full text at CIViC) PMID 23533272 · Sievert et al., 2013 · Open in CIViC |
| civic |
| Selumetinib | Childhood Pilocytic Astrocytoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7486In a phase 2 trial, patients with pediatric low-grade glioma after at least one standard therapy were treated with MEK1/2 inhibitor selumetinib. In stratum 1, nine patients with WHO grade I pilocytic… (full text at CIViC) PMID 31151904 · Fangusaro et al., 2019 · Open in CIViC | civic |
| 〃 | Childhood Pilocytic Astrocytoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID8943In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in… (full text at CIViC) PMID 28002790 · Selt et al., 2017 · Open in CIViC | civic |
| Sorafenib + VemurafenibSubstitutes | Childhood Pilocytic Astrocytoma | Predictive | D | Supports Resistance | 2 | accepted | EID7402A pilocytic astrocytoma (PA) cell line named DKFZ-BT66 was generated from a 2-year old patient with the disease. Expression of KIAA1549-BRAF fusion in this cell line was identified. Treatment with sor… (full text at CIViC) PMID 28002790 · Selt et al., 2017 · Open in CIViC | civic |
| Trametinib | Childhood Pilocytic Astrocytoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID8944In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with trametinib resulted in … (full text at CIViC) PMID 28002790 · Selt et al., 2017 · Open in CIViC | civic |
| Everolimus + TrametinibCombination | Childhood Low Grade Glioma | Predictive | D | Supports Sensitivity Response | 3 | rejected | EID7197This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with… (full text at CIViC) PMID 29156677 · Jain et al., 2017 · Open in CIViC | civic |
| 〃 | Childhood Low Grade Glioma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID7199This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with… (full text at CIViC) PMID 29156677 · Jain et al., 2017 · Open in CIViC | civic |